Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3205855 | 0.90 | NPC1 (0.49) | PLAUATMRAB9AKDM4ENPC1 | |
| SCHEMBL3198296 | 0.85 | PDE10A (0.45) | PLAUATMRAB9AKDM4ENPC1 | |
| SCHEMBL3196195 | 0.85 | PLAU (0.40) | PLAUATMRAB9AKDM4ENPC1 | |
| SCHEMBL3194109 | 0.81 | PLAU (0.42) | PLAUATMRAB9AKDM4ENPC1 | |
| SCHEMBL3202307 | 0.77 | NPC1 (0.46) | PLAURAB9AKDM4ENPC1MAPT | |
| SCHEMBL3198902 | 0.75 | MAPT (0.43) | RAB9AKDM4ENPC1MCHR1MAPT | |
| SCHEMBL3192202 | 0.74 | RAB9A (0.42) | PLAURAB9AKDM4ENPC1MAPT | |
| SCHEMBL3203077 | 0.73 | EPHX2 (0.50) | RAB9ANPC1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL3204779 | 0.73 | MAPT (0.57) | RAB9AKDM4ENPC1MAPTPOLB | |
| SCHEMBL8123880 | 0.73 | DHFR (0.54) | PLAURAB9AKDM4ENPC1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120802-A1 | Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production | MAKOVEC FRANCESCO | 2010-05-13 | — | — | US | disclosed |
| US-7674809-B2 | Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM S.P.A. (IT) | 2010-03-09 | — | — | US | disclosed |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM SPA | 2005-09-08 | — | — | US | disclosed |
| EP-1571142-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | Rottapharm S.p.A. (IT) | 2005-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120802-A1 | Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production | NOS3, NOS1, NOS2 | PLAU 3454/4885ATM 4513/4885RAB9A 2198/4885 |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | NOS3, NOS1, NOS2 | PLAU 3454/4885ATM 4513/4885RAB9A 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.